Tolin David F
The Institute of Living, Anxiety Disorders Center, 200 Retreat Avenue, Hartford, CT 06106, USA.
Psychiatr Clin North Am. 2017 Dec;40(4):715-738. doi: 10.1016/j.psc.2017.08.007. Epub 2017 Sep 18.
The present meta-analysis examined controlled trials of pharmacologic augmentation of cognitive-behavioral therapy (CBT) for patients with anxiety or depressive disorders. The additive effect of medications was small for both anxiety and depressive disorders at posttreatment, and there was no additive benefit after medications were discontinued. A small body of evidence suggested that antidepressant medications are an efficacious second-line treatment for patients failing to respond to CBT alone. In anxiety disorders, novel agents thought to potentiate the biological mechanisms of CBT showed small effects at posttreatment; after discontinuation, some of these agents were associated with an increasing effect.
本荟萃分析研究了针对焦虑症或抑郁症患者的认知行为疗法（CBT）药物增强治疗的对照试验。在治疗后，药物对焦虑症和抑郁症的附加效应均较小，且停药后没有附加益处。一小部分证据表明，抗抑郁药物对于单独接受CBT治疗无效的患者是一种有效的二线治疗方法。在焦虑症中，被认为可增强CBT生物学机制的新型药物在治疗后显示出较小的效果；停药后，其中一些药物的效果有所增强。
